Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept for Anemia in Japanese Patients with Low-Risk MDS
NCT03900715Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- May 2019
- Primary completion
- Jul 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in myelodysplastic syndromes (MDS), sponsored by Celgene Corporation. Primary endpoint: Hematologic Improvement in Erythroid Response at 24 weeks. Started May 2019; status: completed.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT03900715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900715.